Who are Lithium carbonate + perospirone hydrochloride's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Lamotrigine + Aripiprazole.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/lithium-carbonate-perospirone-hydrochloride.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Lithium carbonate + perospirone hydrochloride — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Lithium carbonate + perospirone hydrochloride (Lithium carbonate + perospirone hydrochloride) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Mood stabilizer + atypical antipsychotic combination. Area: Psychiatry.

marketed Mood stabilizer + atypical antipsychotic combination Inositol monophosphatase, GSK-3 (lithium); dopamine D2 receptor, serotonin 5-HT2A receptor (perospirone) Psychiatry Small molecule Live · refreshed every 30 min

Target snapshot

Lithium carbonate + perospirone hydrochloride (Lithium carbonate + perospirone hydrochloride) — Shanghai Mental Health Center. Lithium carbonate modulates intracellular signaling pathways to stabilize mood, while perospirone hydrochloride acts as an atypical antipsychotic by blocking dopamine and serotonin receptors.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Lithium carbonate + perospirone hydrochloride TARGET	Lithium carbonate + perospirone hydrochloride	Shanghai Mental Health Center	marketed	Mood stabilizer + atypical antipsychotic combination	Inositol monophosphatase, GSK-3 (lithium); dopamine D2 receptor, serotonin 5-HT2A receptor (perospirone)
Lamotrigine + Aripiprazole	Lamotrigine + Aripiprazole	Otsuka Pharmaceutical Development & Commercialization, Inc.	marketed	Anticonvulsant/mood stabilizer + atypical antipsychotic combination	Voltage-gated sodium channels (lamotrigine); dopamine D2/D3 receptors (aripiprazole)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Mood stabilizer + atypical antipsychotic combination class)

Shanghai Mental Health Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lithium carbonate + perospirone hydrochloride — Competitive Intelligence Brief. https://druglandscape.com/ci/lithium-carbonate-perospirone-hydrochloride. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab